



PHARMASYNTH

PharmaSynth AS (www.pharmasynth.eu) was founded in 2004 and operates in Tartu Science Park. The company is active in the field of fine organic synthesis, producing precursors and standards of compounds that are used in PET and SPECT imaging in hospitals and diagnostic centers around the globe. The company is registered as an API manufacturer and holds the GMP certificate granted by the Estonian Agency of Medicines. This means manufacturing is made under GMP requirements to assure the quality and reliability of the products.

The list of products includes more than 100 different compounds, mostly used in neuroimaging. For example, many of these products are for early diagnosis of neurodegenerative disorders like Parkinson's and Alzheimer's disease. However, we also satisfy customers' needs in various other areas, developing products used in oncology, cardiology and with other conditions, such as endocrine disorders. Although our focus is on the production of precursors and reference standards for PET and SPECT tracers, we also offer small scale custom synthesis of other organic compounds, including APIs.

The proximity to the University of Tartu offers us several opportunities from analytical services to intellectual partnerships and specialized human resources that enable us to do high quality chemistry research in our labs.



Photo: private collection

Pirkko Irene Penttilä-Hiltunen, Master of Radiochemistry, Doctor of Veterinary Medicine.

Pirkko Irene Penttilä-Hiltunen obtained her master's degree in radiochemistry at the University of Helsinki in 1984 and the diploma of Doctor of Veterinary Medicine at the Estonian University of Life Sciences in 2009. She was among the founders of PharmaSynth AS in 2004 and, since 2022, has been the CEO of this company.